ClinicalTrials.gg
RecruitingNCT07111793IBSoFACToUpdated Oct 13, 2026

Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics

An interventional study of Extended phenotyping and Blood sample for WES in Severe Bacterial Infections, sponsored by Nantes University Hospital. Recruiting at 7 sites in France. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Nantes University Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 13, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,401
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Bacterial Infections with a site in France — 8 open to participants now, 9 under way, none of them phase 3. Bacterial Infections · France.

Planned enrollment
Largest of 25
1,401 · median 142
Started
2026
with 1 other
No phase
12 of 49
3 open now
Registered
47th of 49
by date
Lead sponsor
4 of 49
Nantes University Hospital

Among the 49 studies in Bacterial Infections with a site in France, this one has the largest planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is one of 12 with no phase, and was the 47th registered.

Bacterial Infections

586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

8 of the 49 studies in Bacterial Infections with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Bacterial Infections with a site in France, or all of them as a file.
02

Study summary

Severe bacterial infections (SBI) are responsible for significant morbidity and mortality in the paediatric population. There is considerable individual variability in children's susceptibility to developing SBIs. This variability is multifactorial, and the mechanisms at work are not yet fully understood. The investigators of this study therefore propose to study a population of children who had particularly severe bacterial infections requiring hospitalization in a pediatric intensive care unit in France between 2015 and 2018. This study is part of a global approach to understanding the mechanisms favoring the occurrence of IBS in pediatrics.

The study will initially focus on analyzing the clinical phenotype of these children in terms of the type of infection presented, as well as immunologically with an immune workup of all these patients. The investigators also plan to contact each family individually to identify other episodes of personal or family IBS or other elements suggestive of immune deficiency (opportunistic infections, autoimmune manifestations, severe atopy). The investigators will also assess the persistent sequelae since their infectious episode, and their quality of life following this IBS.

In parallel, the genetic analysis of these patients and their parents will be carried out using whole-exome sequencing. The investigators will compare the results with those obtained in 2 IBS-free control populations (N=70 and N=116). The goal is to identify genetic variants that favor the occurrence of IBS in general, and some that are specific to certain bacteria or clinical presentations.

03

Conditions studied

  • Severe Bacterial Infections

Browse trials for

Keywords

  • Severe bacterial infections
  • Whole-exome sequencing
  • Inborn errors of immunity
  • pediatrics
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For patients:

  • Patient included in the DIABACT IV study between 2015 and 2018, following hospitalization in a pediatric intensive care unit in France for a severe bacterial infection.
  • Patient affiliated to a social security system
  • Patient alive at the time of inclusion.
  • Written consent from legal representatives for participation in research. If one of the legal representatives is unable to complete/sign the written consent, it will be sought orally by telephone and recorded in the patient's file. If the patient is over 18, written consent will be obtained. If the patient is a minor, consent will be sought with communication adapted to his/her level of understanding and age.

For parents:

  • Patient's biological parents
  • Written consent

Exclusion criteria

Exclusion Criteria:

  • Persons under court protection
  • Refusal to participate in research
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,401 participants (estimated)

Study arms

  • Other
    Patients with severe childhood bacterial infections

    Patient inclus dans l'étude DIABACT IV (NCT02167802) entre 2015 et 2018, dans les suites de son hospitalisation en réanimation pédiatrique en France pour une infection bactérienne sévère.

    Other: Extended phenotyping · Other: Blood sample for WES · Other: Blood sample for PBMC freezing · Other: POPC score evaluation · Other: Questionnaire completion

  • Other
    Patient's biological parents

    Other: Blood sample for WES · Other: Questionnaire completion

Interventions

  • OtherExtended phenotyping

    Extended phenotyping (analysis performed at Nantes University Hospital, MANDATORY DELIVERY WITHIN 24 HOURS) = 1 EDTA 3 mL tube for patients included in Nantes.

  • OtherBlood sample for WES

    Blood sample for WES : 1 x 3 mL EDTA tube (if not included in DIABACT IV biocollection)

  • OtherBlood sample for PBMC freezing

    Blood sample for PBMC freezing integrated into the biocollection: 1 EDTA tube = 3 mL

  • OtherPOPC score evaluation

    Assessment of POPC score (Pediatric Overall Performance Category)

  • OtherQuestionnaire completion

    Questionnaires completed by parents or children: * SDQ * PedSQL4.0

06

What researchers measure

Primary outcomes

  1. Identification of innate errors of immunity involved in the development of IBS in pediatrics.

    List of rare genetic variants significantly more frequently found in cases than in controls and/or absent in healthy parents.

    Time frame: At the enrollment

Secondary outcomes

  1. Identification of inborn errors of immunity involved in the development of IBS and their association with abnormalities of the immune balance,

    Time frame: At the enrollment

  2. Identification of rare genetic variants favoring certain clinical types of infection, or certain biological and immunological abnormalities.

    Time frame: At the enrollment

  3. Identification of immune deficiencies in patients who have developed a severe bacterial infection

    Time frame: At the enrollment

  4. Assessment of sequelae with the POPC sequelae score (Pediatric Overall Performance Category) at a distance from the IBS episode.

    The POPC sequelae score is a scale from 1 to 6, with 6 being the worst possible outcome.

    Time frame: At the enrollment

  5. Assessment of sequelae at a distance from the IBS episode with the Strengths and Weaknesses Questionnaire (SDQ-Fra).

    The SDQ-Fra score is a scale from 0 to 2, with 2 being the worst possible outcome.

    Time frame: At the enrollment

  6. Assessment of quality of life at a distance from the IBS episode.

    Quality of life will be assessed in this patient population using the Pediatric Quality of Life InventoryTM (scale from 0 to 4, with 4 corresponding to the worst outcome).

    Time frame: At the enrollment

07

Study locations

1 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 57 non-industry interventional studies with no phase under Bacterial Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 21 months is below that.

Counting every sponsor, half of 61 studies reached it within 24 months; a quarter within 11 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2027 → Dec 2027 and completion Jun 2029 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Aug 8, 2025
StartActual
Mar 18, 2026
Primary completionEst.
Dec 18, 2027was Jun 2027
CompletionEst.
Dec 18, 2029was Jun 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • CHU Montpellier · Montpellier, France
Oct 13, 2026
Primary completion
Jun 1, 2027→Dec 18, 2027
Oct 13, 2026
Study completion
Jun 1, 2029→Dec 18, 2029
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site added
    Show site
    • CHU Montpellier · Montpellier, France
    Primary completion Jun 1, 2027→Dec 18, 2027
    Study completion Jun 1, 2029→Dec 18, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07111793
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Mar 18, 2026
Primary completion
Dec 18, 2027 (estimated)
Completion
Dec 18, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Elise LAUNAY
Contact
elise.launay@chu-nantes.fr
2 40 08 31 79 ext. +33
Sponsor Department
Contact
bp-prom-regl@chu-nantes.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion